English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.  Kirsten rat sarcoma  ( KRAS ) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival, thereby leading to tumorigenesis. Patients whose CRC harbors  KRAS  mutations have a dismal prognosis. Currently,  KRAS  mutation testing is a routine clinical practice before treating metastatic cases, and the approaches developed to detect  KRAS  mutations have exhibited favorable sensitivity and accuracy. Due to the presence of  KRAS  mutations, this group of CRC patients requires more precise therapies. However, KRAS was historically thought to be an undruggable target until the development of KRAS G12C  allele-specific inhibitors. These promising inhibitors may provide novel strategies to treat  KRAS -mutant CRC. Here, we provide an overview of the role of KRAS in the prognosis, diagnosis and treatment of CRC.   Supplementary Information  The online version contains supplementary material available at 10.1186/s12943-021-01441-4.

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer